LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
about
Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteinsHeavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analysesThe crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemiaWhy Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Reduced apolipoprotein glycosylation in patients with the metabolic syndromeA proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes.Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol controlAssociation between hepatic lipase -514 C/T promoter polymorphism and myocardial infarction is modified by history of hypercholesterolemia and waist circumference.Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes.Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial.Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoproteinNon-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence.Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart diseaseHow do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteinsApolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on itApolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in menElectronegative Low-density Lipoprotein Increases Coronary Artery Disease Risk in Uremia Patients on Maintenance HemodialysisIdentification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: the Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan.Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis.Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes.Females with angina pectoris have altered lipoprotein metabolism with elevated cholesteryl ester transfer protein activity and impaired high-density lipoproteins-associated antioxidant enzymes.Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart TrialDisialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetesApolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease.Retinol-binding protein-4 in experimental and clinical metabolic disease.The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women.Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.Factor II activity is similarly increased in patients with elevated apolipoprotein CIII and in carriers of the factor II 20210A allele.Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes MellitusOverexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymphProteomics as a tool to discover biomarkers for the prediction of diabetic complications.
P2860
Q24651503-6850065E-04FC-4F9D-8D07-7353D8BD44F5Q24654726-BF412A12-1E24-4EE1-889C-77A267058350Q26864682-4D43B2D1-ACCE-4B4A-A870-BB7285288763Q28077776-96D9714C-4EE1-4FE6-B532-B81E5B1F6E27Q28541818-9C1CCEE6-EA44-40E3-887F-8AEBADB680A6Q30789864-0C355C40-94B5-4D5D-B5BD-3713ABD4DE5FQ33730396-6FD6C799-CB26-4E37-B4A0-36BC4B49985CQ33915749-3553595B-E27B-4209-97C2-F77BB4CB00BEQ33926736-65F1403F-5A3D-440D-80A2-D5CE5A343F3EQ33962626-640A4E7E-C0D9-4807-B613-5DC4AF368373Q34119914-2B1395B2-EF67-40CE-9A9D-CE3616290E7BQ34441411-FC36E1D2-9052-4208-BD31-3EA3FB87FE88Q34509915-5D01BA71-3B35-48A7-8041-7C48C0CEC3EEQ34668335-D62B1E2A-492F-48BC-BE6E-72C0166006F0Q35628166-0E5AA6AD-CC8D-4C1B-BBCF-2F470B864418Q35738372-31EAE6AD-352E-4631-8661-26D9BC5B22EAQ35839701-CE060600-241F-4F5E-ACEF-E0AEFBACEB09Q35915137-0F94692F-9506-4045-AAD6-3E7D6324714CQ36144245-5A44B057-9505-490B-ADB5-8EA934B15DABQ36366340-CAC199B3-0D6D-45EB-B021-D30F05F459ABQ36368459-339608E6-F795-4896-94F9-D71779985A09Q36377367-77CB8555-1BBE-4771-88E5-844EBA6EE948Q36478016-5F9F91ED-DD5D-405F-AE29-CA5451A71F8CQ36527075-069D2FB3-267D-4716-84B8-176243BB76B9Q36554649-DB0E6EB3-7486-429A-8544-5930224DB635Q36573819-D7A0F0C0-6BD5-4256-8879-EE856A3A2C34Q36623897-8E0DD34A-7681-4F8C-8E92-6E5056E7C6BBQ36807147-91C15E37-B755-4CC4-8262-8AC932517BD4Q36843331-A3B700FA-7D3D-44C8-947E-7A51321BAFC7Q36974283-3ACECD56-E75D-4CB3-91B0-C844A0CD252FQ37206162-5E35AE85-4EC1-4B6D-BFA8-A6C33001ACC2Q37311116-5F396BEA-C043-4EFC-B269-EE7088FD592BQ37317424-22B7CA56-2469-46B6-9E5D-8A3187F862B5Q37326019-5A655D61-F54B-4779-AD40-A9F5D8335152Q37425333-6FA7144E-7A9C-4078-9C42-0F3852BD33A6Q37444625-F39F9650-9326-4131-A513-F938007B2F3EQ37457665-E169070A-A5E4-4DA6-99E6-9E4312C6FBFEQ37468412-2A34D8FD-0E00-4B1B-90E6-B8D921A96089Q37727877-7CA43FC9-9282-4921-8AA0-F5069DB05070Q38089733-619B6E56-F57B-40A7-896F-D3EB65576AD3
P2860
LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
LDL containing apolipoprotein ...... y events in diabetic patients.
@en
LDL containing apolipoprotein ...... y events in diabetic patients.
@nl
type
label
LDL containing apolipoprotein ...... y events in diabetic patients.
@en
LDL containing apolipoprotein ...... y events in diabetic patients.
@nl
prefLabel
LDL containing apolipoprotein ...... y events in diabetic patients.
@en
LDL containing apolipoprotein ...... y events in diabetic patients.
@nl
P2093
P1476
LDL containing apolipoprotein ...... y events in diabetic patients.
@en
P2093
Frank M Sacks
Hannia Campos
Lemuel A Moye
Sung-Joon Lee
P304
P356
10.1161/01.ATV.0000066131.01313.EB
P407
P577
2003-03-13T00:00:00Z